93 related articles for article (PubMed ID: 16261710)
21. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
[No Abstract] [Full Text] [Related]
22. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
23. [Effective combined modality therapy for a patient with primary adrenal lymphoma].
Shirao S; Kuroda H; Kida M; Watanabe H; Matsunaga T; Niitsu Y; Konuma Y; Hirayama Y; Kohda K
Rinsho Ketsueki; 2006 Mar; 47(3):204-9. PubMed ID: 16629485
[TBL] [Abstract][Full Text] [Related]
24. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities.
Wong ET
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7151s-7157s. PubMed ID: 16203815
[TBL] [Abstract][Full Text] [Related]
25. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
Du Y; Honeychurch J; Glennie M; Johnson P; Illidge T
Cancer Res; 2007 Feb; 67(3):1335-43. PubMed ID: 17283171
[TBL] [Abstract][Full Text] [Related]
26. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
27. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP; Goldenberg DM
Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
30. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit.
Wanyura H; Uliasz M; Kaminski A; Samolczyk-Wanyura D; Smolarz-Wojnowska A
J Craniomaxillofac Surg; 2007 Jan; 35(1):39-47. PubMed ID: 17267230
[TBL] [Abstract][Full Text] [Related]
32. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
33. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.
Reagan PM; Friedberg JW
Future Oncol; 2015; 11(10):1543-53. PubMed ID: 25963431
[TBL] [Abstract][Full Text] [Related]
34. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
Jezersek Novaković B; Vovk M; Juznic Setina T
Ann Hematol; 2006 Dec; 85(12):849-56. PubMed ID: 16944146
[TBL] [Abstract][Full Text] [Related]
35. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
Vranovsky A; Ladicka M; Lakota J
Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
[TBL] [Abstract][Full Text] [Related]
37. [Non Hodgkin's lymphomas: a major breakthrough with immunotherapy].
Firescu R; Muylle K; Roelandts M; de Wind A; Moerman C; Lemort M; Kentos A; Meuleman N; Bron D
Rev Med Brux; 2011; 32(2):83-92. PubMed ID: 21688592
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia.
Saga T; Sakahara H; Nakamoto Y; Sato N; Ishimori T; Mamede M; Kobayashi H; Masunaga S; Sasai K; Kuroki M; Konishi J
Eur J Cancer; 2001 Jul; 37(11):1429-34. PubMed ID: 11435076
[TBL] [Abstract][Full Text] [Related]
39. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.
Baues C; Trommer-Nestler M; Jablonska K; Bröckelmann PJ; Schlaak M; von Bergwelt-Baildon M; Engert A; Semrau R; Marnitz S; Theurich S
Immunotherapy; 2017 Mar; 9(5):423-433. PubMed ID: 28357914
[TBL] [Abstract][Full Text] [Related]
40. CCR 20th anniversary commentary: Radioactive Drones for B-cell lymphoma.
Knox SJ; Levy R
Clin Cancer Res; 2015 Feb; 21(3):493-4. PubMed ID: 25646179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
